Health disorders in women can be caused by many abnormalities in the body...
B&W Tek NanoRam Handheld Raman Spectrometer
The NanoRam is a state-of-the-art handheld Ramen instrument for non-destructive identification and verification of incoming raw materials such as active pharmaceutical ingredients (API), excipients, and intermediates.
Deals this week: Ferring Pharmaceuticals, Mirati, Juvenescence
Ferring Pharmaceuticals (US) has entered an exclusive agreement with Sun Pharmaceutical Industries to acquire the commercialisation rights for a generic version of Ganirelix Acetate injection in the US.
M&As this week: Tabula Rasa, Generex, Flex Pharmaceuticals
Tabula Rasa HealthCare has completed the acquisition of DoseMe.
Deals this week: Keros Therapeutics, Opollomics, CANbridge
Keros Therapeutics has raised $23m in series B funding round.
Women’s health pipeline: profiling the GCPR target class
Health disorders in women can be caused by many abnormalities in the body and represent a very broad therapy area. Drug development for women’s health disorders has lagged behind other therapy areas, and few new therapies have been approved in the past years.
Ultomiris (ravulizumab-cwvz) for Paroxysmal Nocturnal Haemoglobinuria
Ultomiris™ (ravulizumab-cwvz) is a complement inhibitor drug approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adults.
Getting Acquainted with the Theory of XRF
This white paper provides a general introduction to X-ray Fluorescence (CRF) spectrometry and XRF analysis. It explains how a spectrometer works and how XRF analysis is achieved.
Chinese biotech hits new heights with approval of first domestic checkpoint inhibitor
On December 17, China’s National Medical Products Authority (NMPA) conditionally approved the listing of the first locally developed programmed cell death-1 (PD-1) checkpoint inhibitor, Tuoyi (toripalimab) monoclonal antibody injection for the treatment of melanoma.
M&As this week: MabSpace Biosciences, Cambrex, Hetero Labs
MabSpace Biosciences has merged with HJB to create a fully-integrated biotherapeutics company named Transcenta Holding.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.